Christopher D. Herzog

Christopher D. Herzog has an extensive background in gene therapy, specifically focusing on rare diseases and neurodegenerative disorders. With research experience spanning over a decade, Christopher has held various leadership roles in companies such as Rocket Pharmaceuticals, Avanir Pharmaceuticals, and Ceregene, Inc. Their expertise in nonclinical research and AAV R&D has enabled him to contribute significantly to the development and commercialization of gene therapies. Christopher holds advanced degrees in Behavioral Neuroscience and has a strong foundation in basic and applied neurochemistry.